Mandate

Vinge advises Industrifonden in connection with its investment in Agteria Biotech

Vinge has advised Industrifonden in connection with their participation as lead investor, together with AgriZeroNZ, in the seed financing round in Agteria Biotech AB.

Agteria Biotech AB is a Swedish start-up dedicated to reducing 1% of the global greenhouse gas emissions through its patent-pending molecule that significantly reduces methane emissions from cattle. The new funding will enable the company to advance towards regulatory approval for its methane-reducing molecule, focusing on safety studies for animals, consumers, and the environment.

The Vinge team consisted primarily of JJohan Larsson, Maria Dahlin Kolvik, Ian Linde (M&A), Åsa Hellstadius, Rebecka Målquist (IP), Simon Söderholm and Agnes Pigg (Employment).

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025